Oppenheimer Raises Price Target on Global Payments (GPN) Following Solid 2Q

Go back to Oppenheimer Raises Price Target on Global Payments (GPN) Following Solid 2Q

Pre-Open Stock Movers 01/09: (ARIA) (MACK) (WOOF) Higher; (ADHD) (AYI) (BABY) Lower (more...)

January 9, 2017 9:25 AM EST

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) 73.4% HIGHER; Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (ARIAD) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and... More

Global Payments (GPN) Tops Q2 EPS by 5c; Raises Outlook

January 9, 2017 7:00 AM EST

Global Payments (NYSE: GPN) reported Q2 EPS of $0.89, $0.05 better than the analyst estimate of $0.84. Revenue for the quarter came in at $817.2 million versus the consensus estimate of $803.55 million.

GUIDANCE:

Global Payments sees FY2017 EPS of $3.70-$3.90, versus the consensus of $3.51. Global Payments sees FY2017 revenue of $3.35-3.45 billion, versus the consensus of $3.25... More